ASX Runners of the Week: Argent, Peregrine, Newpeak Minerals & Caspin
Argent BioPharma Ltd soared as it secured a US$5.5 million deal with Splash Beverage Group for global rights to its CannEpil epilepsy therapy. The deal eliminates approximately US$5.5 million in outstanding convertible notes, easing pressure on Argent’s balance sheet. This agreement marks a significant step for Argent in addressing a critical need in neurology.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 10 Jul 2026, 05:29 UTC · Updated 10 Jul 2026, 05:30 UTC
Summary by OZbrief Editorial. Original report: The West Australian. Editorial policy · Corrections
Trending
- Meet the comedian parodying Karl Stefanovic: ‘He’s cosplaying a conservative’
- Anastasia fought the justice system twice. Her rapist’s punishment has devastated her
- NSW coach Daley slams media over 'hidden agendas' after Origin triumph
- Centenary Pool Complex closes August 30 for 2032 Olympic redevelopment
- Digital guide enhances experience at Museum of the Goldfields
- Severn Trent spared Ofwat fine after ‘serious’ waterwaste and sewage failures